Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Gains from Sales and Divestitures (2017 - 2025)

Historic Gains from Sales and Divestitures for Enanta Pharmaceuticals (ENTA) over the last 9 years, with Q4 2025 value amounting to $147000.0.

  • Enanta Pharmaceuticals' Gains from Sales and Divestitures rose 208.33% to $147000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $147000.0, marking a year-over-year increase of 208.33%. This contributed to the annual value of $152000.0 for FY2025, which is 2459.02% up from last year.
  • As of Q4 2025, Enanta Pharmaceuticals' Gains from Sales and Divestitures stood at $147000.0, which was up 208.33% from $152000.0 recorded in Q3 2025.
  • Enanta Pharmaceuticals' 5-year Gains from Sales and Divestitures high stood at $152000.0 for Q3 2025, and its period low was $29000.0 during Q4 2021.
  • Its 5-year average for Gains from Sales and Divestitures is $86050.0, with a median of $70000.0 in 2023.
  • In the last 5 years, Enanta Pharmaceuticals' Gains from Sales and Divestitures plummeted by 3555.56% in 2021 and then skyrocketed by 14137.93% in 2023.
  • Enanta Pharmaceuticals' Gains from Sales and Divestitures (Quarter) stood at $29000.0 in 2021, then surged by 93.1% to $56000.0 in 2022, then soared by 107.14% to $116000.0 in 2023, then grew by 24.14% to $144000.0 in 2024, then increased by 2.08% to $147000.0 in 2025.
  • Its last three reported values are $147000.0 in Q4 2025, $152000.0 for Q3 2025, and $146000.0 during Q2 2025.